drugset / Trial / NCT04664816

Omega-3 Polyunsaturated Fatty Acids and Non-Muscle Invasive Bladder Cancer

NCT04664816 ↗

Unknown 110 enrolled Mansoura University
RandomizedParallel-groupDouble-blindPrevention

Summary

The investigators hypothesize that omega-3 polyunsaturated fatty acids (n-3 PUFAs) might have a role in prevention of the recurrence of non-muscle invasive bladder cancer (NMIBC). The patients who are suffering from high-risk NMIBC will be randomly allocated into two groups: The first group (n-3 PUFAs group): 55 patients will receive omega-3 plus twice daily for one year after transurethral resection of bladder tumor (TURBT). The second group (Control group): 55 patients will receive placebo twice daily for one year after TURBT. All patients will receive intravesical Bacillus Calmette-Guérin (BCG) immunotherapy and they will be followed up for two years. The chemopreventive effect of n-3 PUFAs on the recurrence of NMIBC after TURBT will be studied via magnetic resonance imaging (MRI), inpatient cystoscopy, histopathological examination and molecular studies of the resected bladder tissues.

Timeline

Start
2020-12-01
Primary completion
2022-12-01
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject n-3PUFAs Treatment Unknown 1200 mg Oral